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Psycho‐Oncology. 2018;1–12.Abstract
Objective: The objective of the study is to investigate the relation between pre-
treatment depressive symptoms (DS) and the course of DS during the first year after
cancer diagnosis, and overall survival among people with head and neck cancer (HNC).
Methods: Data from the Head and Neck 5000 prospective clinical cohort study were
used. Depressive symptoms were measured using the Hospital Anxiety and Depression
Scale (HADS) pretreatment, at 4 and 12‐month follow‐up. Also, socio‐demographic,
clinical, lifestyle, and mortality data were collected. The association between before
start of treatment DS (HADS‐depression > 7) and course (never DS, recovered from
DS, or persistent/recurrent/late DS at 12‐month follow‐up) and survival was investi-
gated using Cox regression. Unadjusted and adjusted analyses were performed.
Results: In total, 384 of the 2144 persons (18%) reported pretreatment DS. Regard-
ing DS course, 63% never had DS, 16% recovered, and 20% had persistent/recurrent/
late DS. People with pretreatment DS had a higher risk of earlier death than people
without DS (hazard ratio (HR) = 1.65; 95% confidence interval (CI) 1.33‐2.05), but this
decreased after correcting for socio‐demographic, clinical, and lifestyle‐related factors
(HR = 1.21; 95% CI 0.97‐1.52). Regarding the course of DS, people with persistent/
recurrent/late DS had a higher risk of earlier death (HR = 2.04; 95% CI 1.36‐3.05), while
people who recovered had a comparable risk (HR = 1.12; 95% CI 0.66‐1.90) as the ref-
erence group who never experienced DS. After correcting for socio‐demographic and
clinical factors, people with persistent/recurrent/late DS still had a higher risk of earlier
death (HR = 1.66; 95% CI 1.09‐2.53).
Conclusions: Pretreatment DS and persistent/recurrent/late DS were associated
with worse survival among people with HNC.
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2 JANSEN ET AL.1 | BACKGROUND
Clinical depression as well as depressive symptoms (DS) have been
reported to increase mortality and reduce survival in different popula-
tions.1-3 Among people with different types of cancer, those with a
clinical diagnosis of minor or major depression have a 39% higher risk
of dying during the follow‐up period than people without depression.1
People with increased levels of DS, as measured using validated
patient‐reported outcome measures, have a 25% higher risk of dying
during the follow‐up period.1
People diagnosed with head and neck cancer (HNC) are prone to
depression or DS.4,5 Previous studies on the association between clini-
cal depression6 or DS7-13 and survival in people with HNC reported
mixed results. Some studies reported no association,7,8 while others
reported worse survival or higher mortality in people with depression
or DS.6,9-13 Half of these studies were, however, limited by small num-
ber of events (eg, disease‐related or overall deaths),7,9-13 hampering
the ability to account for different covariates in the survival analyses.
In addition,most studieswere limited to a singlemeasurement of clinical
depression or DS,7,8,10-13 mostly prior to treatment.7,10-13 As previously
reported,14 pretreatment DS may result from the short‐term response
to cancer diagnosis andmay not necessarily reflect a person's long‐term
course of DS and, therefore, may be a less important associated factor
of survival than DS at follow‐up.
A previous study reports that, in 40% of people with HNC, DS
level indeed changed between the pretreatment and posttreatment
measurement.15 Four different courses of DS were identified: people
without DS, people who developed DS (33%), people who recovered
from DS (7%), and people with persistent DS (4%). A recent study
comparing survival outcomes of people with lung cancer reported on
4 comparable courses of DS.16 They found that people who developed
or had persistent DS had an increased risk of earlier death, while
people who recovered had the same risk as the reference group of
people who never reported DS.
A recent large longitudinal study that measured depression more
than once in people with HNC in relation to survival found that depres-
sion in the 2 years before HNC diagnosis as well as depression in the
year after diagnosis was associated with worsened cancer‐specific and
overall survival.6 In that study, however, no distinction was made
between people who recovered from their depression during
follow‐up and those who did not. In addition, depression was defined
as a registered clinical depression diagnosis based on Medicare claims
data. The generalizability of these findings to people with DS or
undiagnosed depression is unclear.
This study, therefore, aimed to investigate the relation between
pretreatment DS as well as the course of DS during the first year after
cancer diagnosis and overall survival among people with HNC.
2 | METHODS
2.1 | Design and study population
In this study, data from the Head and Neck 5000 prospective clinical
cohort study was used (dataset version 2.1),17,18 including people with
HNC from 76 centers in the United Kingdom. People with HNC wereasked to participate if they had a new primary HNC diagnosis or were
diagnosed with an unknown primary tumor likely to be HNC, and if
they were ≥16 years. People were excluded if they did not have the
capacity to provide informed consent or were too vulnerable for
participation. In total, 5511 persons with HNC consented to partici-
pate from April 2011 to December 2014. For this particular study,
we limited the population to people diagnosed with cancer of the oral
cavity, oropharynx, hypopharynx, or larynx and those treated with
curative intent. Besides, participants needed to have a baseline mea-
surement of DS, and have complete socio‐demographic, clinical, and
lifestyle‐related data.
All participants provided written informed consent. The study was
approved by the National Research Ethics Committee (South West
Frenchay Ethics Committee, reference 10/H0107/57, November 5,
2010), and approved by the research and development departments
for participating NHS Trusts.
2.2 | Measures
The English version of the Hospital Anxiety and Depression Scale
(HADS) was used to assess psychological distress (HADS‐total), level
of DS (HADS‐D), and level of anxiety symptoms (HADS‐A) before
the start of treatment, and at 4 and 12‐month follow‐up.19,20 A
HADS‐D > 7 was used as a cutoff for identifying persons with DS.21
Internal consistency of the HADS‐D in this study was α = .851.
Study‐specific questions were used to measure pretreatment
tobacco use and alcohol consumption. Tobacco use was categorized
as current smoker, former smoker, or never smoked.22 For alcohol
consumption, people were categorized as nondrinkers, moderate
drinkers (1‐14 drinks per week), hazardous drinkers (14‐35 drinks/
week for women and 14‐50 drinks/week for men), or harmful drinkers
(>35 drinks/week for women and >50 drinks/week for men).22 In
addition, age, gender, marital status, education level, annual household
income, and deprivation status were measured. Deprivation status
was measured using the Index of Multiple Deprivation (IMD) 2010.23
2.3 | Clinical information
Clinical information was abstracted from the hospital information
system and patients' notes by research nurses. Clinical information
included the primary International Classification of Diseases (ICD)
2010 diagnosis, intended and actual received treatment, Adult Comor-
bidity Evaluation (ACE‐27), TNM‐stage, and human papilloma virus
(HPV) status. Human papilloma virus status was based on serology
data, and defined as positive where HPV16E6 was positive (>1000
median fluorescence intensity).24 At the start of the study, participants
were flagged with the United Kingdom Health and Social Care
Information Centre so that the study team was provided with
information on overall mortality (mortality and mortality date).
2.4 | Statistical analyses
All analyses were performed using the IBM Statistical Package for the
Social Science (SPSS) version 23 (IBM Corp., Armonk, NY USA).
Chi‐square tests and independent samples t‐test analyses were used
to analyze differences between groups.
JANSEN ET AL. 3To assess the association between pretreatment DS and overall
survival, a series of Cox regression analyses were performed. At first,
minimally adjusted analyses adjusted for age and gender were per-
formed. Analyses were performed in the total population as well as
in people with oral cavity, HPV‐positive oropharyngeal, and HPV‐neg-
ative oropharyngeal and laryngeal cancer separately. Survival time was
defined as days from date of consent to censoring or date of death.
Besides these minimally adjusted analyses, we investigated whether
potential associations remained after adjusting for socio‐demographic
and clinical factors. Also, Cox regression analyses adjusted for life-
style‐related factors were performed. Previous literature hypothesized
that lifestyle may mediate the association between depression or DS
and survival.3,25 However, other studies added lifestyle as a potential
confounder to the model.7,8 Results can, therefore, be interpreted
either as the direct effect after taking the potential mediating role of
lifestyle into account or as the association that remains after adjusting
for lifestyle as a potential confounder. Finally, post hoc analyses were
performed by including each factor 1 by 1 to the minimally adjusted
model, to investigate which factors had a strong influence on the
association between DS and survival (defined as >10% change in haz-
ard ratio (HR)). All categorical variables adhered to the proportional
hazard assumption. Multicollinearity was not found.
Besides analyses on the association between pretreatment DS
and survival, unadjusted and adjusted Cox regression analyses were
performed using the course of DS in the first year after diagnosis as
potential associated factor. For these analyses, people needed to have,
besides the previously discussed eligibility criteria, complete HADS‐D
at 4 and 12‐month follow‐up, and complete information on actual
received treatment. All people were classified according to their
course of DS15,16: never DS (below threshold at all measurements),
recovered from DS (above threshold at baseline and/or 4‐month
follow‐up, but recovered at 12‐month follow‐up), or persistent/recur-
rent/late DS (above threshold at 12‐month follow‐up, regardless of
outcome at baseline and 4‐month follow‐up). To prevent immortal
time bias, landmark analyses with survival time defined as days
between 12‐month follow‐up and date of censoring or death were
performed.26,27 Immortal time bias is bias resulting from misclassifying
immortal time, ie, the time period during which the participants could
not have been dead (in this case time between baseline and 12 months
follow‐up), as survival time.3 | RESULTS
The HADS‐D score of the total study population (n = 2144) was on
average 4.0 (standard deviation = 3.8, range 0‐21). Eighteen percent
(n = 384) had pretreatment DS (Table 1, Appendices 1 and 2). Median
follow‐up was 1046 days (range 601‐1963). Overall, 439 (20%) people
died during the follow‐up period, of whom 332 were in the group
without (19%) and 107 in the group with DS (28%). Mean survival time
was 1509 days (95% confidence interval (CI) 1436‐1582) for the
group with and 1651 days (95% CI 1620‐1682) for the group
without DS.
People with pretreatment DS had a higher risk of earlier death com-
pared to people without DS (HR = 1.65; 95% CI 1.33‐2.05) (Table 2,
Appendix 3). After adjustment for other socio‐demographic factors aswell as for socio‐demographic and clinical factors, the strength of the
association decreased (HR = 1.49; 95% CI 1.19‐1.86 and HR = 1.29;
95% CI 1.03‐1.62, respectively). After additional adjustment for poten-
tial mediation or confounding by lifestyle, the direct association further
decreased (HR = 1.21; 95% CI 0.97‐1.52). Post hoc analyses showed
that comorbidity (12% change), income (11% change), and smoking
(10% change) had a major influence on the association.
Subgroup analyses were performed for people with oral cavity,
HPV‐positive oropharyngeal, and HPV‐negative oropharyngeal and
laryngeal cancer. A higher risk of earlier death was found in people
with oral cavity (HR = 1.88; 95% CI 1.30‐2.71) and HPV‐negative
oropharyngeal (HR = 1.80; 95% CI 1.05‐3.08) and laryngeal cancer
(HR = 1.77; 95% CI 1.09‐2.88) with DS, compared to people without
DS, while no such association was found among people with HPV‐
positive oropharyngeal cancer (HR = 0.75; 95% CI 0.34‐1.66)
(Table 2). After additional adjustment, the strength of the associations
decreased (Table 2).3.1 | Association between the course of depressive
symptoms and overall survival
Of the 2144 people in the original sample, 1217 completed the
HADS‐D at follow‐up (Appendix 1). The other 927 either died before
the end of the first year (19%) or had missing follow‐up data (81%). Of
the 1217 people, 445 (37%) experienced DS during the first year after
treatment (13% pretreatment, 29% at 4‐month follow‐up, and 20% at
12‐month follow‐up). Regarding their course of DS in the first year after
diagnosis: 63% were categorized as never had DS (n = 772), 16% as
recovered from DS (n = 198), and 20% as having persistent/recurrent/
late DS (respectively 7%, 1%, and 12%) (n = 247) (Appendix 1). The 3
groups differed on all characteristics, except gender (Appendix 4).
Median follow‐up from 12 months onwards was 676 days (range
236‐1598). In total, 123 (10%) people died during this follow‐up
period, of whom 66 never had DS (9%), 18 had recovered from DS
(9%), and 39 had persistent/recurrent/late DS (16%). Using people
who never experienced DS as a reference group, it was found that
those with persistent/recurrent/late DS had a HR of 2.04 (95% CI
1.36‐3.05), while people who recovered from DS had a comparable
hazard as the reference group (HR = 1.12; 95% CI 0.66‐1.90)
(Table 3 and Appendix 3). After adjustment for other socio‐demo-
graphic factors as well as for socio‐demographic and clinical factors,
the HR of the group with persistent/recurrent/late DS compared to
the reference group further decreased (HR = 1.88; 95% CI 1.25‐2.84
and HR = 1.66; 95% CI 1.09‐2.53). For the group who recovered from
DS the findings remained stable (HR = 1.10, 95% CI 0.65‐1.86 and
HR = 1.06; 95% CI 0.62‐1.83). Post hoc analyses showed that tumor
location (18% change), comorbidity (17% change), and income (10%
change) had a major influence on the association.4 | DISCUSSION
Using data from the Head and Neck 5000 study,17,18 it was found that
13% to 18% of people with HNC experience pretreatment DS. During
the first year after diagnosis, 63% of people with HNC never had DS,
16% recovered from DS, and 20% had persistent/recurrent/late DS.
TABLE 1 Characteristics of the groups with and without pretreatment depressive symptoms
Baseline Characteristics
Population Without Depressive Symptoms
(HADS‐D ≤ 7)
Population with Depressive Symptoms
(HADS‐D > 7)
n = 1760 n = 384
Frequency Percentage Frequency Percentage P Value
Socio‐demographic
Age .023
18‐50 years 229 13.0% 53 13.8%
50‐64 years 868 49.3% 218 56.8%
65‐79 years 583 33.1% 99 25.8%
80 and older 80 4.5% 14 3.6%
Gender .267
Men 1353 76.9% 285 74.2%
Women 407 23.1% 99 25.8%
Marital status .001
Single/widowed/divorced 550 31.3% 155 40.4%
Married or living with a partner 1210 68.8% 229 59.6%
Education level .001
School education 777 44.1% 192 50.0%
College 615 34.9% 143 37.2%
Degree 368 20.9% 49 12.8%
Annual household income <.001
<£18 000 737 41.9% 233 60.7%
£18 000‐£34 999 537 30.5% 101 26.3%
>£35 000 486 27.6% 50 13.0%
IMD quintiles <.001
Low deprivation 762 43.3% 119 31.0%
Moderate deprivation 401 22.8% 82 21.4%
High deprivation 597 33.9% 183 47.7%
Clinical
Tumor location .442
Oral cavity 503 28.6% 104 27.1%
Oropharynx 800 45.5% 173 45.1%
Hypopharynx 69 3.9% 22 5.7%
Larynx 388 22.0% 85 22.1%
Tumor stage .028
Stage I 428 24.3% 66 17.2%
Stage II 297 16.9% 69 18.0%
Stage III 216 12.3% 53 13.8%
Stage IV 819 46.5% 196 51.0%
Intended treatment .655
Surgery 558 31.7% 112 29.2%
Radiotherapy 344 19.5% 73 19.0%
Chemoradiation 595 33.8% 142 37.0%
Surgery and adjuvant therapy 263 14.9% 57 14.8%
Comorbidity <.001
No comorbidity 883 50.2% 136 35.4%
Mild decompensation 560 31.8% 132 34.4%
Moderate/severe decompensation 317 18.0% 116 30.2%
HPV status (oropharyngeal cancer only)a .025
Positive 508 73.3% 95 64.2%
Negative 185 26.7% 53 35.8%
(Continues)
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TABLE 1 (Continued)
Baseline Characteristics
Population Without Depressive Symptoms
(HADS‐D ≤ 7)
Population with Depressive Symptoms
(HADS‐D > 7)
n = 1760 n = 384
Frequency Percentage Frequency Percentage P Value
Lifestyle
Tobacco usage <.001
Current smoker 310 17.6% 112 29.2%
Former smoker 1,012 57.5% 211 54.9%
Never smoked 438 24.9% 61 15.9%
Alcohol consumption <.001
Nondrinker 412 23.4% 131 34.1%
Moderate drinker 420 23.9% 51 13.3%
Hazardous drinker 676 38.4% 133 34.6%
Harmful drinker 252 14.3% 69 18.0%
aHPV status is missing in 132 persons.
JANSEN ET AL. 5Pretreatment DS and persistent/recurrent/late DS during the first
year were found to be associated with worse overall survival among
people with HNC.
This study showed that participants with pretreatment DS had a
higher risk of earlier death compared to those without DS after
adjusting for socio‐demographic and clinical factors. In addition, we
found that, in people with oral cavity and HPV‐negative oropharyn-
geal and laryngeal cancer, DS were associated with worse survival,
while in people with HPV‐positive oropharyngeal cancer, no such
association was found. Previous studies on the association between
pretreatment DS and overall survival have shown inconsistent
results.7,10-13 Two studies in people with different types of HNC
found no evidence for such an association (after adjustment),7,11 while
Shinn et al10 targeting people with oropharyngeal cancer, Zimmaro
et al12 targeting people with mixed HNC treated with (chemo)radia-
tion, and Chen et al also targeting people with mixed HNC reported
an increased risk of earlier death or poorer overall survival among
those with pretreatment DS. In contrast to our study, Shinn et al10
did not stratify for HPV status, as HPV status was only available for
a subsample. Nevertheless, they reported no differences in HPV status
between those with and without pretreatment DS, while we found
such a difference. The inconsistent results of the different studies
may be because of the limited statistical power resulting from small
sample sizes (130 to 241 persons) in combination with low number
of events (18 to 48 persons died during follow‐up).7,10-13 In our
analyses, data from 2144 people were analyzed, of whom 439 (20%)
died during the follow‐up period, which provided us with the opportu-
nity to stratify our analyses and to adjust for a wide range of potential
confounders. However, for the stratified analyses, additional analyses
replicating our findings are warranted.
Besides worse survival in people with pretreatment DS, we also
found that those with persistent/recurrent/late DS have higher risk
of earlier death compared to the reference group of people who never
experienced DS during the first year, while people who recovered
from DS had the same risk. This is in line with results of a study among
people with lung cancer.16 These findings suggest that, as previously
hypothesized,14 people who have persistent DS or develop DS at fol-
low‐up have worse survival.The pathways via which DS may influence survival are still
unclear.1-3,25 A hypothesized pathway is that DS negatively influences
lifestyle, which consequently worsens survival. To provide insight into
the potential mediating role of lifestyle, we performed extra analyses
in which we adjusted for tobacco and alcohol consumption. We found
that after this adjustment, the strength of the association diminished,
but remained evident. This suggests that lifestyle may explain part of
the pathway between DS and survival, but not all. However, as
lifestyle data were limited to pretreatment data, more research is
needed on the causal role of lifestyle.
Another pathway may be that untreated depression can cause
suicide.25 Although suicide is, compared to other diseases, relatively
common among people with HNC,28 in absolute terms, it is a rare
event. Also, tumor‐related and patient‐related biomarkers of
endocrine, immune, and autonomic (dys)function or other clinical var-
iables may explain the association between depression and survival.25
This might explain why we found a potential association between pre-
treatment DS and overall survival in people with HPV‐negative oro-
pharyngeal cancer and not in HPV‐positive oropharyngeal cancer.
However, future research is warranted to replicate these findings
and to explore the specific role of HPV status and other biomarkers.
4.1 | Study limitations
A limitation of this study was the missing data which may have
influenced representativeness of findings and generalizability to the
HNC population. Also, people with HNC were dichotomized based
on a HADS‐D cutoff score of 7,21 while a score of 1 to 7 may already
be indicative of mild DS. Finally, only information on DS and overall
survival were available; further studies on clinical depression and
disease‐specific survival are warranted.
4.2 | Clinical implications
People with pretreatment DS as well as persistent/recurrent/late DS
are at increased risk of earlier death. Previous studies have hypothe-
sized that lifestyle and suicide may explain (part of) this association.
Also, tumor‐related or patient‐related biomarkers are hypothesized
to mediate this association.
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TABLE 3 Cox regression analyses on the association between the course of depressive symptoms and overall survival
Model
All Head and Neck Cancers N = 1217
HR
95% CI
P Value
Lower Upper
Base case model (adjusted for age and gender)a
Never depressive symptoms Reference .002
Recovered from depressive symptoms 1.12 0.66 1.90
Persistent/recurrent/late depressive symptoms 2.04 1.36 3.05
Model adjusted for socio‐demographic characteristicsb
Never depressive symptoms Reference .009
Recovered from depressive symptoms 1.10 0.65 1.86
Persistent/recurrent/late depressive symptoms 1.88 1.25 2.84
Model adjusted for socio‐demographic and clinical
characteristicsc
Never depressive symptoms Reference .054
Recovered from depressive symptoms 1.06 0.62 1.83
Persistent/recurrent/late depressive symptoms 1.66 1.09 2.53
HR, hazard ratio; 95% CI, 95% confidence interval; HADS‐D, Hospital Anxiety and Depression Scale ‐Depression; HPV, human papilloma virus.
aThe base case analysis is adjusted for age and gender.
bAdjusted for age, gender, marital status, education level, income, and IMD deprivation score.
cAdjusted for age, gender, marital status, education level, income, IMD deprivation score, tumor location, tumor stage, actual received treatment, and
comorbidity.
JANSEN ET AL. 75 | CONCLUSION
Results of this study indicate that people with pretreatment DS as well
as persistent/recurrent/late DS are at increased risk of earlier death.
Further research is needed on potential pathways via which
depression or DS may influence survival.
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10.1002/pon.4816APPENDIX 1. FLOW DIAGRAM*927 HNC persons did not have complete HADS‐D data at 4 and 12‐month follow‐up, because they died before the end of the first year
(19%) or dropped out or had missing data (81%).1 Never depressive symptoms (n = 772);2 Recovered from depressive symptoms before start
of treatment or 4 months follow‐up (n = 198);3 Persistent/recurrent/late depressive symptoms at 12‐months follow‐up (n = 247).
JANSEN ET AL. 9APPENDIX 2. COMPARISON OF PEOPLE WITH COMPLETE HADS‐D, SOCIO‐DEMOGRAPHIC,
CLINICAL DATA, AND LIFESTYLE DATA (N = 2144) , COMPARED TO PEOPLE WITH MISSING
DATA (N = 2306)Baseline Characteristics
Population with Complete Data Population with Missing Data
n = 2144 n = 2306
Frequency Percentage Frequency Percentage P Value
Socio‐demographic
Mean age (SD) 60.9 (10.5) 62.7 (11.0) <.001
Gender .062
Men 1,638 76.4% 1,706 74.0%
Women 506 23.6% 600 26.0%
Clinical
Tumor location (ICD) <.001
Oral cavity 607 28.3% 692 30.0%
Oropharynx 973 45.4% 905 39.2%
Hypopharynx 91 4.2% 125 5.4%
Larynx 473 22.1% 584 25.3%
Tumor stage .622
Stage I 494 23.0% 509 22.1%
Stage II 366 17.1% 419 18.2%
Stage III 269 12.5% 303 13.2%
Stage IV 1,015 47.3% 1,068 46.5%
Missing 0 7
Intended treatment <.001
Surgery 670 31.3% 764 33.1%
Radiotherapy 417 19.4% 507 22.0%
Chemoradiation 737 34.4% 631 27.4%
Surgery and adjuvant therapy 320 14.9% 404 17.5%
Status .008
Alive 1,705 79.5% 1,757 76.2%
Died 439 20.5% 549 23.8%
10 JANSEN ET AL.APPENDIX 3. SURVIVAL CURVES
a) Survival analysis on pretreatment depressive symptoms adjusted for socio‐demographic and clinical characteristics and potential mediation or
confounding by lifestyle factorsb) Survival analysis on the course of depressive symptoms adjusted for socio‐demographic and clinical characteristicsPretreatment Depressive Symptoms Course of Depressive Symptoms
Number at Risk (Number Censored) per Time Point Number at Risk (Number Censored per Time Point)
0 days 500 days 1000 days 1500 days 0 days 250 days 500 days 750 days 1000 days 1250 days
No 1760 (0) 1584 (0) 811 (643) 170 (1261) Never symptoms 772 (0) 752 (3) 528 (194) 308 (401) 143 (565) 47 (659)
Yes 384 (0) 322 (0) 160 (121) 35 (242) Recovered from
symptoms
198 (0) 191 (3) 120 (64) 70 (112) 38 (143) 12 (168)
Persistent, recurrent
or late symptoms
247 (0) 226 (1) 157 (58) 96 (116) 46 (165) 20 (189)
JANSEN ET AL. 11APPENDIX 4. POPULATION CHARACTERISTICS OF THE GROUPS WITH DIFFERENT COURSES
OF DEPRESSIVE SYMPTOMSNever Depressive
Symptomsa
N = 772
Recovered from Depressive
Symptomsb
N = 198
Persistent/Recurrent/Late
Depressive Symptoms
12‐month Follow‐Upc
N = 247
Frequency Percentage Frequency Percentage Frequency Percentage P Value
Socio‐demographic
Age <.001
18‐50 years 80 10.4% 19 9.6% 27 10.9%
50‐64 years 360 46.6% 120 60.6% 148 59.9%
65‐79 years 292 37.8% 51 25.8% 67 27.1%
80 and older 40 5.2% 8 4.0% 5 2.0%
Gender .564
Men 591 76.6% 145 73.2% 184 74.5%
Women 181 23.4% 53 26.8% 63 25.5%
Marital status .016
Single, widowed or divorced 205 26.6% 51 25.8% 88 35.6%
Married/living with a partner 567 73.4% 147 74.2% 159 64.4%
Highest education level .001
School education 302 39.1% 83 41.9% 128 51.8%
College 289 37.4% 62 31.3% 85 34.4%
Degree 181 23.4% 53 26.8% 34 13.8%
Annual household income <.001
Less than £18 000 280 36.3% 69 34.8% 137 55.5%
£18 000‐£34 999 244 31.6% 69 34.8% 74 30.0%
More than £35 000 248 32.1% 60 30.3% 36 14.6%
IMD quintiles (2010) <.001
Low deprivation 387 50.1% 92 46.5% 86 34.8%
Moderate deprivation 171 22.2% 45 22.7% 54 21.9%
High deprivation 214 27.7% 61 30.8% 107 43.3%
Clinical
Tumor location (ICD) <.001
Oral cavity 252 32.6% 34 17.2% 63 25.5%
Oropharynx 302 39.1% 138 69.7% 127 51.4%
Hypopharynx 18 2.3% 5 2.5% 9 3.6%
Larynx 200 25.9% 21 10.6% 48 19.4%
Tumor stage <.001
Stage I 249 32.3% 18 9.1% 47 19.0%
Stage II 143 18.5% 22 11.1% 49 19.8%
Stage III 94 12.2% 24 12.1% 33 13.4%
Stage IV 286 37.0% 134 67.7% 118 47.8%
Actual received treatment <.001
Surgery 221 28.6% 20 10.1% 51 20.6%
Radiotherapy 162 21.0% 22 11.1% 43 17.4%
Chemoradiation 221 28.6% 118 59.6% 100 40.5%
Surgery and adjuvant therapy 168 21.8% 38 19.2% 53 21.5%
Comorbidity index <.001
No comorbidity 407 52.7% 106 53.5% 94 38.1%
Mild decompensation 250 32.4% 62 31.3% 84 34.0%
Moderate/severe decompensation 115 14.9% 30 15.2% 69 27.9%
(Continued)
Never Depressive
Symptomsa
N = 772
Recovered from Depressive
Symptomsb
N = 198
Persistent/Recurrent/Late
Depressive Symptoms
12‐month Follow‐Upc
N = 247
Frequency Percentage Frequency Percentage Frequency Percentage P Value
Lifestyle
Tobacco usage <.001
Current smoker 94 12.2% 25 12.6% 62 25.1%
Former smoker 467 60.5% 110 55.6% 137 55.5%
Never smoked 211 27.3% 63 31.8% 48 19.4%
Alcohol consumption .001
Nondrinker 168 21.8% 45 22.7% 76 30.8%
Moderate drinker 207 26.8% 46 23.2% 37 15.0%
Hazardous drinker 301 39.0% 72 36.4% 92 37.2%
Harmful drinker 96 12.4% 35 17.7% 42 17.0%
aHADS‐D below threshold at all measurements.
bHADS‐D above threshold at baseline and/or 4‐month follow‐up, but recovered at 12‐month follow‐up.
cHADS‐D above threshold at 12‐month follow‐up, regardless of outcome at baseline and 4‐month follow‐up.
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